Gluconorm PG 2 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (1000mg), and Pioglitazone (15mg), formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, facilitating better glycemic control than monotherapy. Gluconorm PG 2 Forte is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used under medical supervision, with monitoring for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, weight gain, and rare risks including lactic acidosis and fluid retention. Dose adjustments may be necessary based on renal function and clinical response. This formulation supports improved patient compliance through once-daily dosing with sustained-release properties.